EktaH Links Novel Obesity Drug to Fat Loss, Muscle Retention in Early-Phase Trial

Why It Matters

Targeting fat‑taste receptors offers a physiologic alternative to GLP‑1 therapies, potentially delivering weight loss without the muscle loss and gastrointestinal side effects that limit current treatments.

Key Takeaways

• Early trial shows 4.3% fat mass loss with NKS‑5 after four weeks
• Fat‑taste receptor agonists also increased skeletal muscle by 0.36%
• 15 of 18 participants responded, indicating broad applicability
• Preclinical data suggest NKS‑3 may preserve lean mass post‑GLP‑1
• EktaH plans Phase 2 trial in 2025, enrolling 126 patients for 12 weeks

Pulse Analysis

EktaH’s approach pivots on reactivating CD36 and GPR120 receptors, which are down‑regulated in many individuals with obesity. By delivering synthetic fatty‑acid agonists orally, the company seeks to restore the tongue’s ability to detect dietary fat, thereby enhancing satiety signals at the source. Early clinical data suggest this mechanism can produce measurable fat‑mass reductions while preserving—or even modestly increasing—lean muscle, a rare combination in the weight‑loss arena.

The market for oral anti‑obesity drugs is currently dominated by GLP‑1 analogues from Novo Nordisk and Eli Lilly, which achieve rapid weight loss but often trigger gastrointestinal discomfort and loss of muscle mass. EktaH’s candidates differentiate themselves by targeting a distinct physiological pathway, offering a potential maintenance therapy after GLP‑1 treatment and a solution for patients who do not respond to existing injectables. Preclinical mouse studies indicate that NKS‑3 can halve weight regain while protecting lean tissue, positioning the drug as a complementary option rather than a direct competitor.

Looking ahead, EktaH intends to launch a 12‑week Phase 2 trial with 126 obese participants later next year, while completing a larger 120‑subject study by December. The company is already engaging regulators and courting investors to fund the next development stage. If the Phase 2 results confirm the early signals, EktaH could capture a niche of patients seeking weight‑loss therapies that maintain muscle health, potentially reshaping the competitive dynamics of the burgeoning oral obesity‑drug market.